HCW Biologics Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Otsuka Pays $10m Up Front For Ion

The pace of cancer partnering between the biopharma industry and academic and institutional research entities during the final months of 2022 remained typically brisk, and two US institutions – The U

With understanding of immune function advancing in leaps and bounds and a continuing proliferation of tools to manipulate it, expectations are high for advances in oncology and immunology over the com

It remains to be seen whether the performance of biopharmaceutical company initial public offerings in the US this year will cause investors to rethink their strategies but returns from IPOs so far th